Effectiveness Study of GSK Biologicals' Rotarix TM Vaccine in Hospitalized Children
NCT01177826 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 643
Last updated 2020-01-03
Summary
The purpose of this study is to assess vaccine effectiveness of Rotarix in preventing rotavirus severe gastroenteritis among hospitalized infants, in Belgium.
Conditions
- Infections, Rotavirus
- Rotavirus Vaccines
Interventions
- PROCEDURE
-
Sample collection
Stool sample
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
GSK Clinical Trials · GlaxoSmithKline
Eligibility
- Min Age
- 14 Weeks
- Max Age
- 5 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-02-23
- Primary Completion
- 2010-06-11
- Completion
- 2010-06-11
Countries
- Belgium
Study Locations
More Related Trials
-
Long-term Efficacy and Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GSK Bio's HRV Vaccine.
NCT00420316 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
NCT02914184 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Test 2 Doses of the HRV Vaccine in Healthy Infants.
NCT00140673 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate Immunogenicity, Reactogenicity and Safety of Rotarix™ Vaccine in Korean Infants
NCT00969228 ·Status: COMPLETED ·Phase: PHASE4
-
Immunogenicity, Reactogenicity and Safety Study of Two Different Formulations of GSK Biologicals' Human Rotavirus Vaccine, Rotarix, in Healthy Infants
NCT02141204 ·Status: COMPLETED ·Phase: PHASE3
-
Study of 2 Doses of HRV Vaccine Given Concomitantly With Routine EPI Vaccinations Including OPV in Healthy Infants
NCT00139347 ·Status: COMPLETED ·Phase: PHASE3
-
Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine at Different Viral Concentrations in Healthy Infants
NCT00429481 ·Status: COMPLETED ·Phase: PHASE2
-
Serologic Response to Porcine Circovirus Type 1 (PCV-1) in Infants Following Administration of Rotarix™
NCT02153333 ·Status: COMPLETED
-
Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in 2-doses in Healthy Chinese Infants Starting at Age 6-16 Weeks
NCT06025695 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy, Safety, Reactogenicity & Immunogenicity of the Rotarix Vaccine in Japanese Infants
NCT00480324 ·Status: COMPLETED ·Phase: PHASE3
-
Study of 2 Doses of Oral Live Attenuated Human Rotavirus (HRV) Vaccine for the Prophylaxis of Rotavirus Gastroenteritis
NCT00134732 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Reactogenicity and Safety of Rotarix™ in Chinese Adults
NCT01162590 ·Status: COMPLETED ·Phase: PHASE1
-
Assessment of Clinical Consistency of Three Production Lots of GSK Biologicals' HRV Vaccine
NCT00757770 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Explore the Existence of Horizontal Transmission of the RIX4414 Vaccine Strain Between Twins Within a Family.
NCT00396630 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix (Human Rotavirus Vaccine) in Infants
NCT00750893 ·Status: COMPLETED
-
Vaccine Efficacy Against Rotavirus Diarrhea; Vaccine Given With Routine Childhood Vaccinations in Healthy African Infants
NCT00241644 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants
NCT00197210 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluate Protective Efficacy of Diff Strengths of Human Rotavirus Vaccine After Admn of 2 Doses to Infants Aged 2 Months
NCT00385320 ·Status: COMPLETED ·Phase: PHASE2
-
To Evaluate Safety & Reactogenicity of GSK Bio's Human Rotavirus (HRV) Vaccine in Filipino Infants at Least 6 Weeks of Age at First Vaccination
NCT00353366 ·Status: COMPLETED
-
Safety Study of GSK Biologicals' Rotavirus Vaccine (Rotarix®) Administered to Children Aged <1 Year in the United States
NCT00875641 ·Status: COMPLETED
-
Study of Two Doses of GSK Biologicals' Live Attenuated HRV Vaccine (Two Different Formulations) in Healthy Infants.
NCT00729001 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Assess the Safety of GSK Biologicals' Liquid Human Rotavirus Vaccine in Healthy Infants
NCT01107587 ·Status: COMPLETED ·Phase: PHASE1
-
Assess the Immunogenicity of the Human Rotavirus (HRV) Vaccine After Reconstitution Without Buffering Agent; & Evaluate the Immunogenicity, Reactogenicity & Safety of the Vaccine After Storage for 7 d at 37°C Following 2 Doses in Healthy Infants
NCT00169455 ·Status: COMPLETED ·Phase: PHASE3
-
A Study in Infants to Test Two Preparations (Freeze-dried or Liquid) of the Rotavirus Vaccine (HRV Vaccine).
NCT00382772 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Safety, Reactogenicity and Immunogenicity of HRV Vaccine in HIV Infected Infants in South Africa
NCT00263666 ·Status: COMPLETED ·Phase: PHASE2